HTG Releases Proof-of-Approach Whitepaper Establishing Utility of Transcriptome-Informed Approach to Drug Discovery

TUCSON, Ariz. , March 31, 2022 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, has released its first proof-of-approach white paper (the “White Paper”),